Analyst Price Targets — BMEA
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| March 24, 2025 1:27 pm | — | Oppenheimer | $10.00 | $2.79 | TheFly | Biomea Fusion price target lowered to $10 from $50 at Oppenheimer |
| October 31, 2024 7:29 am | Joseph Catanzaro | Piper Sandler | $19.00 | $10.34 | TheFly | Biomea Fusion price target raised to $19 from $10 at Piper Sandler |
| October 30, 2024 4:44 am | Peter Lawson | Barclays | $11.00 | $12.06 | TheFly | Biomea Fusion price target raised to $11 from $9 at Barclays |
| October 22, 2024 6:58 am | Joseph Pantginis | H.C. Wainwright | $40.00 | $11.24 | StreetInsider | H.C. Wainwright Reiterates Buy Rating on Biomea Fusion Inc. (BMEA) |
| September 27, 2024 8:41 am | Joseph Catanzaro | Piper Sandler | $10.00 | $9.90 | StreetInsider | Piper Sandler Reiterates Overweight Rating on Biomea Fusion Inc. (BMEA) |
| June 7, 2024 8:34 am | Joseph Pantginis | H.C. Wainwright | $15.00 | $4.24 | TheFly | Biomea Fusion price target lowered to $15 from $50 at H.C. Wainwright |
| June 7, 2024 7:25 am | George Farmer | Scotiabank | $21.00 | $11.27 | StreetInsider | Biomea Fusion Inc. (BMEA) PT Lowered to $21 at Scotiabank |
| June 7, 2024 4:48 am | Peter Lawson | Barclays | $5.00 | $11.27 | TheFly | Biomea Fusion downgraded to Equal Weight from Overweight at Barclays |
| June 14, 2022 11:04 am | Joseph Pantginis | H.C. Wainwright | $16.00 | $8.50 | Pulse 2.0 | Biomea Fusion (BMEA) Stock Price: $16 Target And Buy Rating |
Latest News for BMEA
Shares of Biomea Fusion Inc (NASDAQ:BMEA) are trading sharply higher on Monday following an operational milestone for its lead metabolic drug program.
SAN CARLOS, Calif., Aug. 24, 2026 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea,” “Biomea Fusion” or the “Company”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity medicines company, today announced the completion of enrollment in COVALENT-211, a randomized, double-blinded, placebo-controlled Phase II clinical trial evaluating icovamenib in patients with insulin-deficient T2D who remain inadequately…
Citi analyst Yigal Nochomovitz sees enormous upside in two biotech stocks, but those forecasts reveal as much about risk as potential reward. Nochomovitz has a $7 target on Biomea Fusion, implying about 410% upside from the price used in Citi's call, while his $57 Syndax Pharmaceuticals target points to roughly 190%.
• Initiated Study to Assess the Potential Impact of the Combination of Icovamenib and Low-Dose Semaglutide on Physical Function, Body Weight, Body Composition, Muscle Health, and Metabolic Outcomes
SAN CARLOS, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or “Biomea Fusion” or “the Company”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today reported its financial results for the second quarter ended June 30, 2026, and provided a business update.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for BMEA.
U.S. House Trading
No House trades found for BMEA.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.